Female and Male Pelvic Health Issues deserve the very best medical attention.

Count on us for the private, personal, & professional attention you need.

The Center for Pelvic Medicine

The Center for Pelvic Medicine is a national leader in treating female and male pelvic health problems.

We provide convenient access to advanced care for conditions in female and male urinary and pelvic health.

 

Effective October 1, 2016 Center for Pelvic Medicine will no longer be accepting insurance for payment.

Read the full Announcement

Dr. Susan Kellogg Spadt, PhD, CRNP, IF, FCST

Dr. Susan Kellogg Spadt, PhD, CRNP, IF, FCST is the Director of Female Sexual Medicine at the Center for Pelvic Medicine, Member of the editorial board of The Journal of Sexual Medicine.

 

Elizabeth Kusturiss, MSN, CRNP

Elizabeth Kusturiss, MSN, CRNPis a Nurse Practitioner in Female Sexual Medicine at the Center for Pelvic Medicine.

News

Follow @Doctor_Kellogg

September 13, 2016: Effective October 1, 2016 Center for Pelvic Medicine will no longer be accepting insurance for payment

Read the full Announcement

June 7, 2015: Dr. Kellogg Approves Female Libido Pill Flibanserin CBS News

Dr. Kellogg CBS News Approves Flibanserin  first FDA Libido drug Approved for Women.

 VIDEO

Get “the little pink pill” Flibanserin used For Women with low desire low sex drive from Center for Pelvic Medicine in Rosemont PA

The pill is to boost women’s sexual desire. The “little pink pill” is one step closer to going on the market. After saying no twice, an FDA panel finally recommended the first medication for female sexual dysfunction. Unlike  drugs for men, like Viagra, which improve blood flow, Flibanserin is an anti-depressant that works on the pleasure center of the brain.

The pill, however, comes with side effects, which include insomnia, nausea and dizziness. As always, women will need to decide whether the risks versus the benefits compared to other treatment alternatives are worth it for them.

The panel of Food and Drug Administration advisers voted 18-6 in favor of Sprout Pharmaceutical’s daily pill, flibanserin, on the condition that the company develops a plan to manage its risks.